NATCO PHARMA | IPCA LABS | NATCO PHARMA/ IPCA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 30.6 | 21.1 | 145.1% | View Chart |
P/BV | x | 4.4 | 7.5 | 57.7% | View Chart |
Dividend Yield | % | 0.8 | 0.2 | 482.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NATCO PHARMA Mar-19 |
IPCA LABS Mar-19 |
NATCO PHARMA/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 849 | 1,042 | 81.5% | |
Low | Rs | 557 | 590 | 94.4% | |
Sales per share (Unadj.) | Rs | 573.8 | 298.6 | 192.2% | |
Earnings per share (Unadj.) | Rs | 176.0 | 35.0 | 502.9% | |
Cash flow per share (Unadj.) | Rs | 198.2 | 49.4 | 400.9% | |
Dividends per share (Unadj.) | Rs | 6.25 | 3.00 | 208.3% | |
Dividend yield (eoy) | % | 0.9 | 0.4 | 241.8% | |
Book value per share (Unadj.) | Rs | 842.7 | 247.1 | 341.0% | |
Shares outstanding (eoy) | m | 36.50 | 126.35 | 28.9% | |
Bonus/Rights/Conversions | BB | ESOS | - | ||
Price / Sales ratio | x | 1.2 | 2.7 | 44.8% | |
Avg P/E ratio | x | 4.0 | 23.3 | 17.1% | |
P/CF ratio (eoy) | x | 3.5 | 16.5 | 21.5% | |
Price / Book Value ratio | x | 0.8 | 3.3 | 25.3% | |
Dividend payout | % | 3.6 | 8.6 | 41.4% | |
Avg Mkt Cap | Rs m | 25,660 | 103,108 | 24.9% | |
No. of employees | `000 | 5.0 | 13.4 | 36.9% | |
Total wages/salary | Rs m | 3,559 | 7,874 | 45.2% | |
Avg. sales/employee | Rs Th | 4,225.3 | 2,807.0 | 150.5% | |
Avg. wages/employee | Rs Th | 718.0 | 585.8 | 122.6% | |
Avg. net profit/employee | Rs Th | 1,295.9 | 329.0 | 393.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,945 | 37,732 | 55.5% | |
Other income | Rs m | 1,302 | 577 | 225.7% | |
Total revenues | Rs m | 22,247 | 38,309 | 58.1% | |
Gross profit | Rs m | 7,948 | 6,901 | 115.2% | |
Depreciation | Rs m | 810 | 1,824 | 44.4% | |
Interest | Rs m | 193 | 189 | 102.3% | |
Profit before tax | Rs m | 8,247 | 5,465 | 150.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,823 | 1,042 | 174.9% | |
Profit after tax | Rs m | 6,424 | 4,422 | 145.3% | |
Gross profit margin | % | 37.9 | 18.3 | 207.5% | |
Effective tax rate | % | 22.1 | 19.1 | 115.9% | |
Net profit margin | % | 30.7 | 11.7 | 261.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 23,472 | 23,778 | 98.7% | |
Current liabilities | Rs m | 7,287 | 10,975 | 66.4% | |
Net working cap to sales | % | 77.3 | 33.9 | 227.7% | |
Current ratio | x | 3.2 | 2.2 | 148.7% | |
Inventory Days | Days | 92 | 104 | 88.9% | |
Debtors Days | Days | 88 | 66 | 133.8% | |
Net fixed assets | Rs m | 18,648 | 20,368 | 91.6% | |
Share capital | Rs m | 365 | 253 | 144.4% | |
"Free" reserves | Rs m | 34,525 | 30,971 | 111.5% | |
Net worth | Rs m | 30,760 | 31,224 | 98.5% | |
Long term debt | Rs m | 0 | 1,409 | 0.0% | |
Total assets | Rs m | 43,031 | 45,507 | 94.6% | |
Interest coverage | x | 43.7 | 30.0 | 146.0% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.8 | 58.7% | |
Return on assets | % | 15.4 | 10.1 | 151.8% | |
Return on equity | % | 20.9 | 14.2 | 147.5% | |
Return on capital | % | 27.4 | 17.3 | 158.4% | |
Exports to sales | % | 0 | 45.9 | 0.0% | |
Imports to sales | % | 0 | 16.6 | 0.0% | |
Exports (fob) | Rs m | NA | 17,308 | 0.0% | |
Imports (cif) | Rs m | NA | 6,266 | 0.0% | |
Fx inflow | Rs m | 11,536 | 17,308 | 66.6% | |
Fx outflow | Rs m | 2,939 | 6,266 | 46.9% | |
Net fx | Rs m | 8,597 | 11,042 | 77.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,688 | 4,923 | 135.9% | |
From Investments | Rs m | -6,122 | -1,563 | 391.7% | |
From Financial Activity | Rs m | -509 | -1,832 | 27.8% | |
Net Cashflow | Rs m | 66 | 1,528 | 4.3% |
Indian Promoters | % | 52.0 | 45.9 | 113.4% | |
Foreign collaborators | % | 1.5 | 0.0 | - | |
Indian inst/Mut Fund | % | 7.8 | 11.4 | 68.8% | |
FIIs | % | 16.6 | 25.3 | 65.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 26.0 | 17.4 | 149.4% | |
Shareholders | 25,395 | 36,892 | 68.8% | ||
Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare NATCO PHARMA With: TTK HEALTHCARE ALEMBIC DR. REDDYS LAB ELDER PHARMA SUVEN LIFE SCIENCES
Compare NATCO PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge buying interest during the extended closing hours yesterday and ended on a strong note.
For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsIn this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More